UK becomes world’s first nation to approve AstraZeneca-Oxford Covid vaccine


Britain on Wednesday became the first country in the world to approve a developed by and as it battles a major winter surge driven by a new, highly contagious variant of the virus.

said the authorisation was for a two dose regime, and that the vaccine had been approved for use for emergency supply. Britain has ordered 100 million doses of the vaccine.


.




“The government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise Oxford University/AstraZeneca’s COVID-19 vaccine for use,” the health ministry said.


.


The pandemic has already killed 1.7 million people around the world, sown chaos through the global economy and upended normal life for billions since it began in Wuhan, China, a year ago.


.


Britain and South Africa in particular are grappling with new variants of the coronavirus, which the government and scientists say are more contagious; many countries have responded by banning passenger flights and blocking trade.


.

and other developers have said they are studying the impact of the new variant but expect that their shots will be effective against it.


.

Regulatory endorsement is a welcome boost for AstraZeneca and the Oxford team, which have been accused of a lack of clarity about the results from late-stage trials.


Pooled results from those trials show it had overall efficacy was 70.4%. Efficacy was 62% for trial participants given two full doses, but 90% for a smaller sub-group given a half, then a full dose.

.


Researchers said that the finding of 90% efficacy for the low-dose/high-dose regime needed more investigation. AstraZeneca did not specify which dose regime had been approved.

.

“Today is an important day for millions of people in the UK who will get access to this new vaccine,” AstraZeneca Chief Executive Pascal Soriot said.


“It has been shown to be effective, well-tolerated, simple to administer and is supplied by AstraZeneca at no profit.”

.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor




First Published: Wed, December 30 2020. 12:43 IST

































Source link